Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CEO Jeffrey M. Dayno Sells 19,293 Shares

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) CEO Jeffrey M. Dayno sold 19,293 shares of the firm’s stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $40.13, for a total value of $774,228.09. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Harmony Biosciences Stock Down 1.7 %

Shares of HRMY stock opened at $38.01 on Friday. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. The stock’s 50-day simple moving average is $34.66 and its 200-day simple moving average is $35.05. Harmony Biosciences Holdings, Inc. has a fifty-two week low of $28.14 and a fifty-two week high of $41.61. The firm has a market capitalization of $2.17 billion, a PE ratio of 18.01, a P/E/G ratio of 0.53 and a beta of 0.78.

Harmony Biosciences (NASDAQ:HRMY) last posted its quarterly earnings data on Tuesday, October 29th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.64 by $0.15. Harmony Biosciences had a return on equity of 23.16% and a net margin of 17.98%. The firm had revenue of $186.00 million during the quarter, compared to the consensus estimate of $184.07 million. During the same period in the prior year, the company earned $0.63 EPS. The firm’s revenue was up 16.0% compared to the same quarter last year. Equities analysts expect that Harmony Biosciences Holdings, Inc. will post 2.43 earnings per share for the current year.

Institutional Investors Weigh In On Harmony Biosciences

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Envestnet Asset Management Inc. lifted its holdings in Harmony Biosciences by 19.8% in the second quarter. Envestnet Asset Management Inc. now owns 61,397 shares of the company’s stock valued at $1,852,000 after acquiring an additional 10,167 shares during the period. Dimensional Fund Advisors LP lifted its holdings in shares of Harmony Biosciences by 13.3% during the 2nd quarter. Dimensional Fund Advisors LP now owns 956,785 shares of the company’s stock worth $28,871,000 after acquiring an additional 112,197 shares during the period. Hsbc Holdings PLC boosted its holdings in Harmony Biosciences by 208.1% in the second quarter. Hsbc Holdings PLC now owns 23,800 shares of the company’s stock valued at $731,000 after acquiring an additional 16,076 shares during the last quarter. Profund Advisors LLC boosted its position in Harmony Biosciences by 11.1% during the 2nd quarter. Profund Advisors LLC now owns 7,557 shares of the company’s stock worth $228,000 after purchasing an additional 758 shares during the period. Finally, Public Sector Pension Investment Board raised its stake in shares of Harmony Biosciences by 2.9% during the second quarter. Public Sector Pension Investment Board now owns 70,020 shares of the company’s stock valued at $2,113,000 after purchasing an additional 1,955 shares during the period. 86.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. Needham & Company LLC reiterated a “buy” rating and issued a $52.00 target price on shares of Harmony Biosciences in a research report on Monday, January 13th. Mizuho raised their target price on Harmony Biosciences from $42.00 to $52.00 and gave the company an “outperform” rating in a research note on Thursday, October 10th. Oppenheimer reissued an “outperform” rating and issued a $59.00 price objective (up from $56.00) on shares of Harmony Biosciences in a research note on Wednesday, October 30th. Cantor Fitzgerald upped their price objective on Harmony Biosciences from $51.00 to $58.00 and gave the company an “overweight” rating in a research note on Wednesday, October 30th. Finally, Raymond James reissued an “outperform” rating and issued a $40.00 price objective on shares of Harmony Biosciences in a report on Thursday, October 10th. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average target price of $55.00.

About Harmony Biosciences

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.